Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, abatacept (Orencia®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate. |
||
|
||
Medicine details |
||
| Medicine name | abatacept (Orencia®) | |
| Formulation | 125 mg solution for injection and 250 mg powder for concentrate for solution for infusion | |
| Reference number | 2985 | |
| Indication | In combination with methotrexate for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate. |
|
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 17/11/2016 | |